Thermo Fisher Scientific agrees to sell its microbiology business to private equity firm Astorg for over $1 billion.
Thermo Fisher Scientific has agreed to divest its microbiology business to Astorg, a private equity firm, for more than $1 billion. The deal represents a significant asset sale by Thermo Fisher as it continues to reshape its portfolio. No closing date has been publicly specified in the available reporting.
8
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Wall Street Journal
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Both outlets report the same deal; Reuters leads with the $1 billion-plus price tag, while WSJ's headline omits the figure, leaving Reuters as the source for specific deal valuation.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion - Reuters”
“Thermo Fisher to Sell Microbiology Business to Astorg - WSJ”
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed